PureTech Health plc

PureTech Health plc, a biopharmaceutical company established in Boston, Massachusetts, in 2015, functions as a clinical-stage firm primarily within the United States. It is dedicated to discovering, developing, and bringing to market medical treatments for a wide range of severe conditions, including inflammatory, fibrotic, and immunological diseases, challenging cancers, lymphatic and gastrointestinal disorders, and various neurological and neuropsychological ailments. The company's portfolio features KarXT, a therapy targeting muscarinic acetylcholine receptors for schizophrenia and psychosis associated with Alzheimer's disease. PureTech also employs a regenerative biology platform to address issues like androgenetic alopecia and epithelial aging, alongside an immunomodulation platform for both acute and chronic inflammatory disorders. Additional offerings include oral therapies derived from specific bacterial consortia of the human microbiome, and interventions for cognitive dysfunction often accompanying depression, multiple sclerosis, post-COVID, ICU recovery, and cancer-related conditions. Its technological innovations further encompass hematopoietic stem cell-based therapies for blood cancers, a voice-analysis platform for identifying health shifts, and a specialized technology enabling the oral delivery of biologics, vaccines, and other complex drugs. Currently in development, PureTech is advancing LYT-100 for lymphedema and other lymphatic flow disorders, as well as LYT-200 (an IgG4 monoclonal antibody designed to target galectin-9) and LYT-210, both aimed at solid tumors. Its pipeline also leverages advanced platforms such as Glyph for synthetic lymphatic targeting chemistry, Orasome technology for the oral administration of macromolecule payloads, a meningeal lymphatics platform addressing Alzheimer's and Parkinson's diseases, and the Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc maintains significant collaboration and licensing agreements with notable pharmaceutical partners, including Boehringer Ingelheim International GMBH, Eli Lilly and Company, Imbrium Therapeutics L.P., and Shionogi & Co., Ltd.